Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients

Doxorubicin (DOX) is often first-line treatment of undifferentiated/unclassified soft tissue sarcoma (USTS). However, the DOX response rate for USTS patients is low. Individualized precision-medicine technology that could identify DOX responders as well as non-responders would be of high value to ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Kawaguchi, Kei, Igarashi, Kentaro, Kiyuna, Tasuku, Miyake, Kentaro, Miyake, Masuyo, Murakami, Takashi, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Singh, Arun S., Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969558/
https://ncbi.nlm.nih.gov/pubmed/29384032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1421876
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados